{"id":6165,"date":"2022-12-02T02:51:25","date_gmt":"2022-12-02T02:51:25","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=6165"},"modified":"2023-08-29T17:56:24","modified_gmt":"2023-08-29T17:56:24","slug":"pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=6165","title":{"rendered":"PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f"},"content":{"rendered":"<p>PharmAust (ASX: PAA) \u5df2\u7ecf\u62db\u52df\u4e86\u7b2c\u4e00\u4e2a\u60a3\u8005\u961f\u5217\u8fdb\u884c 1\/2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6d4b\u8bd5\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269\u83ab\u5948\u592a\u5c14 (MPL) \u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\/\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7 (MND\/ALS) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002<\/p>\n<p>\u7b2c\u4e00\u4e2a\u961f\u5217\u5305\u62ec 6 \u540d MND \u60a3\u8005\uff0c\u4ed6\u4eec\u90fd\u63a5\u53d7\u4e86\u4ed6\u4eec\u7684\u7b2c\u4e00\u4e2a MPL \u6cbb\u7597\u6c34\u5e73\uff0c\u201c\u8010\u53d7\u6027\u826f\u597d\u201d\u3002<\/p>\n<p>\u60a3\u8005\u5728\u4e24\u4e2a\u5730\u70b9\u62db\u52df\uff1a\u7ef4\u591a\u5229\u4e9a\u5dde\u7684 Calvary Health Care Bethlehem \u548c\u9ea6\u8003\u745e\u5927\u5b66\u4f4d\u4e8e\u65b0\u5357\u5a01\u5c14\u58eb\u5dde\u7684\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\u7814\u7a76\u4e2d\u5fc3\u3002<\/p>\n<p>1\/2 \u671f\u7814\u7a76\u65e8\u5728\u786e\u5b9a MND \u60a3\u8005\u53e3\u670d MPL \u7684\u8010\u53d7\u6027\u3001\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u521d\u6b65\u7597\u6548\u3002<\/p>\n<p>\u8fd9\u9879\u7814\u7a76\u662f\u5f00\u653e\u6807\u7b7e\u7684\uff0c\u5305\u62ec\u4e3a\u671f 4 \u5468\u7684\u9012\u589e\u5242\u91cf\u7684 MPL\u3002<\/p>\n<h2>\u201c\u8010\u53d7\u6027\u826f\u597d\u201d\u7684\u5242\u91cf<\/h2>\n<p>\u7531\u4e8e\u7b2c\u4e00\u4e2a\u5242\u91cf\u6c34\u5e73\u201c\u8010\u53d7\u6027\u826f\u597d\u201d\uff0c\u4e0b\u4e00\u6b21\u5242\u91cf\u5347\u7ea7\u7684\u60a3\u8005\u62db\u52df\u5c06\u5728\u65b0\u7684\u4e00\u5e74\u5f00\u59cb\u3002<\/p>\n<p>\u5c06\u8bc4\u4f30\u6240\u6709\u5242\u91cf\u6c34\u5e73\u7684\u4e25\u91cd\u4e0d\u826f\u4e8b\u4ef6\u3001\u4e0d\u826f\u4e8b\u4ef6\u3001\u5b89\u5168\u8840\u6db2\u7ed3\u679c\u3001\u5fc3\u7535\u56fe\u3001\u751f\u547d\u4f53\u5f81\u548c\u836f\u4ee3\u52a8\u529b\u5b66\u3002<\/p>\n<p>\u5ba1\u6838\u5c06\u5728\u961f\u5217\u4e2d\u7684\u6700\u540e\u4e00\u540d\u53c2\u4e0e\u8005\u5b8c\u6210\u7b2c 29 \u5929\u540e\u5b8c\u6210\u3002<\/p>\n<p>\u201c\u968f\u7740\u6211\u4eec\u5728 MND \u4e2d\u8fdb\u884c\u836f\u4ee3\u52a8\u529b\u5b66\u8bc4\u4f30\uff0cMPL \u6c34\u5e73\u7684\u9010\u6e10\u5347\u9ad8\u5c06\u6709\u52a9\u4e8e\u786e\u5b9a\u6211\u4eec\u660e\u5e74\u8fdb\u884c\u7684 COVID \u8bd5\u9a8c\u7684\u5b89\u5168\u5242\u91cf\u6c34\u5e73\u3002<\/p>\n<p>FightMND \u5728\u627f\u8bfa\u603b\u8ba1 881,085 \u6fb3\u5143\u540e\u534f\u52a9\u4e3a\u8bd5\u9a8c\u63d0\u4f9b\u8d44\u91d1\uff0c\u5728\u8fbe\u5230\u67d0\u4e9b\u91cc\u7a0b\u7891\u540e\u5206\u671f\u652f\u4ed8\u3002<\/p>\n<h2>\u5173\u4e8e MPL<\/h2>\n<p>MPL \u662f\u4e00\u79cd\u65b0\u578b\u3001\u6709\u6548\u4e14\u5b89\u5168\u7684 mTOR \u901a\u8def\u6291\u5236\u5242\uff0c\u5bf9\u764c\u75c7\u751f\u957f\u548c\u795e\u7ecf\u751f\u6210\u6027\u75be\u75c5\u5177\u6709\u201c\u5173\u952e\u5f71\u54cd\u201d\u3002<\/p>\n<p>\u9664\u4e86\u8bc4\u4f30 MND \/ ALS \u4e2d\u7684 MPL \u4e4b\u5916\uff0cPharmAust \u8fd8\u5728\u7814\u7a76\u8be5\u836f\u7269\u5bf9\u4eba\u7c7b\u548c\u72ac\u79d1\u52a8\u7269\u7684\u6297\u764c\u4f5c\u7528\u3002<\/p>\n<p>\u5bf9\u72ac\u79d1\u52a8\u7269\u7684\u6700\u65b0\u7814\u7a76\u7ed3\u679c\u8868\u660e\uff0cMPL \u53ef\u4ee5\u4f7f\u60a3\u6709\u764c\u75c7\u7684\u72d7\u7684\u9884\u671f\u5bff\u547d\u5ef6\u957f\u4e00\u500d\u4ee5\u4e0a\u3002<\/p>\n<p>\u5728\u6700\u8fd1\u8bca\u65ad\u4e3a\u5e7c\u7a1a B \u7ec6\u80de\u6dcb\u5df4\u7624\u4e14\u4e4b\u524d\u672a\u63a5\u53d7\u6cbb\u7597\u7684\u72ac\u79d1\u52a8\u7269\u7684 2a \u548c 2b \u671f\u8bd5\u9a8c\u4e2d\uff0cMPL \u5df2\u8bc1\u660e\u5177\u6709\u6709\u6548\u7684\u6297\u764c\u6d3b\u6027\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PharmAust (ASX: PAA) \u5df2\u7ecf\u62db\u52df\u4e86\u7b2c\u4e00\u4e2a\u60a3\u8005\u961f\u5217\u8fdb\u884c 1\/2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6d4b\u8bd5\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269\u83ab\u5948\u592a\u5c14 (MPL) \u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\/\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7 (MND\/ALS) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002 \u7b2c\u4e00\u4e2a\u961f\u5217\u5305\u62ec 6 \u540d MND \u60a3\u8005\uff0c\u4ed6\u4eec\u90fd\u63a5\u53d7\u4e86\u4ed6\u4eec\u7684\u7b2c\u4e00\u4e2a MPL \u6cbb\u7597\u6c34\u5e73\uff0c\u201c\u8010\u53d7\u6027\u826f\u597d\u201d\u3002 \u60a3\u8005\u5728\u4e24\u4e2a\u5730\u70b9\u62db\u52df\uff1a\u7ef4\u591a\u5229\u4e9a\u5dde\u7684 Calvary Health Care Bethlehem \u548c\u9ea6\u8003\u745e\u5927\u5b66\u4f4d\u4e8e\u65b0\u5357\u5a01\u5c14\u58eb\u5dde\u7684\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\u7814\u7a76\u4e2d\u5fc3\u3002 1\/2 \u671f\u7814\u7a76\u65e8\u5728\u786e\u5b9a MND \u60a3\u8005\u53e3\u670d MPL \u7684\u8010\u53d7\u6027\u3001\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u521d\u6b65\u7597\u6548\u3002 \u8fd9\u9879\u7814\u7a76\u662f\u5f00\u653e\u6807\u7b7e\u7684\uff0c\u5305\u62ec\u4e3a\u671f 4 \u5468\u7684\u9012\u589e\u5242\u91cf\u7684 MPL\u3002 \u201c\u8010\u53d7\u6027\u826f\u597d\u201d\u7684\u5242\u91cf \u7531\u4e8e\u7b2c\u4e00\u4e2a\u5242\u91cf\u6c34\u5e73\u201c\u8010\u53d7\u6027\u826f\u597d\u201d\uff0c\u4e0b\u4e00\u6b21\u5242\u91cf\u5347\u7ea7\u7684\u60a3\u8005\u62db\u52df\u5c06\u5728\u65b0\u7684\u4e00\u5e74\u5f00\u59cb\u3002 \u5c06\u8bc4\u4f30\u6240\u6709\u5242\u91cf\u6c34\u5e73\u7684\u4e25\u91cd\u4e0d\u826f\u4e8b\u4ef6\u3001\u4e0d\u826f\u4e8b\u4ef6\u3001\u5b89\u5168\u8840\u6db2\u7ed3\u679c\u3001\u5fc3\u7535\u56fe\u3001\u751f\u547d\u4f53\u5f81\u548c\u836f\u4ee3\u52a8\u529b\u5b66\u3002 \u5ba1\u6838\u5c06\u5728\u961f\u5217\u4e2d\u7684\u6700\u540e\u4e00\u540d\u53c2\u4e0e\u8005\u5b8c\u6210\u7b2c 29 \u5929\u540e\u5b8c\u6210\u3002 \u201c\u968f\u7740\u6211\u4eec\u5728 MND \u4e2d\u8fdb\u884c\u836f\u4ee3\u52a8\u529b\u5b66\u8bc4\u4f30\uff0cMPL \u6c34\u5e73\u7684\u9010\u6e10\u5347\u9ad8\u5c06\u6709\u52a9\u4e8e\u786e\u5b9a\u6211\u4eec\u660e\u5e74\u8fdb\u884c\u7684 COVID \u8bd5\u9a8c\u7684\u5b89\u5168\u5242\u91cf\u6c34\u5e73\u3002 FightMND \u5728\u627f\u8bfa\u603b\u8ba1 881,085 \u6fb3\u5143\u540e\u534f\u52a9\u4e3a\u8bd5\u9a8c\u63d0\u4f9b\u8d44\u91d1\uff0c\u5728\u8fbe\u5230\u67d0\u4e9b\u91cc\u7a0b\u7891\u540e\u5206\u671f\u652f\u4ed8\u3002 \u5173\u4e8e MPL MPL \u662f\u4e00\u79cd\u65b0\u578b\u3001\u6709\u6548\u4e14\u5b89\u5168\u7684 mTOR \u901a\u8def\u6291\u5236\u5242\uff0c\u5bf9\u764c\u75c7\u751f\u957f\u548c\u795e\u7ecf\u751f\u6210\u6027\u75be\u75c5\u5177\u6709\u201c\u5173\u952e\u5f71\u54cd\u201d\u3002&hellip; <a class=\"more-link\" href=\"https:\/\/smallcapscn.x5view.co\/?p=6165\">Continue reading <span class=\"screen-reader-text\">PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":17918,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[241],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f<\/title>\n<meta name=\"description\" content=\"PharmAust (ASX: PAA) \u5df2\u7ecf\u62db\u52df\u4e86\u7b2c\u4e00\u4e2a\u60a3\u8005\u961f\u5217\u8fdb\u884c 1\/2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6d4b\u8bd5\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269\u83ab\u5948\u592a\u5c14 (MPL) \u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\/\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7 (MND\/ALS) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f\" \/>\n<meta property=\"og:description\" content=\"PharmAust (ASX: PAA) \u5df2\u7ecf\u62db\u52df\u4e86\u7b2c\u4e00\u4e2a\u60a3\u8005\u961f\u5217\u8fdb\u884c 1\/2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6d4b\u8bd5\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269\u83ab\u5948\u592a\u5c14 (MPL) \u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\/\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7 (MND\/ALS) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-02T02:51:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:56:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/PharmAust-ASX-PAA-monepantel-MPL-First-Patient-Cohort-Motor-Neurone-Disease-Amyotrophic-Lateral-Sclerosis-MND-ALS.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/\",\"name\":\"PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-12-02T02:51:25+00:00\",\"dateModified\":\"2023-08-29T17:56:24+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"PharmAust (ASX: PAA) \u5df2\u7ecf\u62db\u52df\u4e86\u7b2c\u4e00\u4e2a\u60a3\u8005\u961f\u5217\u8fdb\u884c 1\/2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6d4b\u8bd5\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269\u83ab\u5948\u592a\u5c14 (MPL) \u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\/\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7 (MND\/ALS) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f","description":"PharmAust (ASX: PAA) \u5df2\u7ecf\u62db\u52df\u4e86\u7b2c\u4e00\u4e2a\u60a3\u8005\u961f\u5217\u8fdb\u884c 1\/2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6d4b\u8bd5\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269\u83ab\u5948\u592a\u5c14 (MPL) \u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\/\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7 (MND\/ALS) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f","og_description":"PharmAust (ASX: PAA) \u5df2\u7ecf\u62db\u52df\u4e86\u7b2c\u4e00\u4e2a\u60a3\u8005\u961f\u5217\u8fdb\u884c 1\/2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6d4b\u8bd5\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269\u83ab\u5948\u592a\u5c14 (MPL) \u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\/\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7 (MND\/ALS) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/","og_site_name":"smallcapsCN","article_published_time":"2022-12-02T02:51:25+00:00","article_modified_time":"2023-08-29T17:56:24+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/PharmAust-ASX-PAA-monepantel-MPL-First-Patient-Cohort-Motor-Neurone-Disease-Amyotrophic-Lateral-Sclerosis-MND-ALS.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/","url":"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/","name":"PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-12-02T02:51:25+00:00","dateModified":"2023-08-29T17:56:24+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"PharmAust (ASX: PAA) \u5df2\u7ecf\u62db\u52df\u4e86\u7b2c\u4e00\u4e2a\u60a3\u8005\u961f\u5217\u8fdb\u884c 1\/2 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6d4b\u8bd5\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269\u83ab\u5948\u592a\u5c14 (MPL) \u5728\u8fd0\u52a8\u795e\u7ecf\u5143\u75be\u75c5\/\u808c\u840e\u7f29\u6027\u4fa7\u7d22\u786c\u5316\u75c7 (MND\/ALS) \u60a3\u8005\u4e2d\u7684\u7597\u6548\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/pharmaust-first-patient-cohort-enrolment-initial-dosing-mpl-trial-mnd-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"PharmAust \u5b8c\u6210\u4e86 MND \u60a3\u8005 MPL \u8bd5\u9a8c\u7684\u9996\u6b21\u60a3\u8005\u961f\u5217\u767b\u8bb0\u548c\u521d\u59cb\u7ed9\u836f"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6165"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6165"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6165\/revisions"}],"predecessor-version":[{"id":16044,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6165\/revisions\/16044"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/17918"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}